Xifaxan is a prescription-only antibiotic marketed under the brand name Xifaxan. Its active ingredient is rifaximin, a rifamycin-derived compound that works primarily within the gastrointestinal (GI) tract. The medication is supplied as oral pills in strengths of 200 mg, 400 mg, and 550 mg. In Hong Kong, Xifaxan is regulated by the Pharmacy and Poisons Board and can be dispensed only with a medical prescription. The product is manufactured by Salix Pharmaceuticals, a subsidiary of Bausch Health.
Rifaximin belongs to the class of non-systemic antibiotics. After oral ingestion, less than 0.5 % of the dose is absorbed into the bloodstream, allowing it to act locally in the gut lumen. The drug binds to the β-subunit of bacterial DNA-dependent RNA polymerase, inhibiting transcription and ultimately killing susceptible bacteria. Because it remains largely confined to the GI tract, rifaximin exerts minimal systemic effects while targeting a broad spectrum of gram-positive and gram-negative organisms.
Key pharmacologic features:
Xifaxan is approved by major regulatory agencies (U.S. FDA, European EMA, and the Hong Kong Pharmacy and Poisons Board) for the following indications:
These uses are based on robust clinical trial data demonstrating symptom relief, reduced ammonia production in hepatic encephalopathy, and decreased bowel habit irregularities in IBS-D.
Research and clinical guidelines have explored additional applications of rifaximin, though they are not formally approved:
Off-label use of Xifaxan is not approved by the Hong Kong regulatory authorities; it should only be undertaken under direct medical supervision.
These events are typically transient and resolve without intervention.
Patients should report any new or worsening gastrointestinal symptoms, especially signs of C. difficile infection.
This article provides educational information about Xifaxan and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
Xifaxan is indicated for the treatment of traveler's diarrhea after symptoms begin. It is not approved for prophylactic use; travelers should follow standard preventive measures such as safe food and water practices.
A rash may signal an allergic reaction. Discontinue the medication and seek immediate medical attention, especially if the rash is accompanied by swelling, difficulty breathing, or fever.
Rifaximin is frequently prescribed for hepatic encephalopathy, which occurs in patients with chronic liver disease. However, individuals with severe, acute liver failure should avoid the drug. Mild to moderate liver impairment is generally acceptable under physician supervision.
Rifaximin remains largely confined to the gastrointestinal tract, producing minimal systemic exposure, whereas ciprofloxacin is absorbed systemically and has a broader range of tissue distribution and systemic side effects.
There is no direct contraindication, but because rifaximin reduces gut bacterial load, it may temporarily diminish probiotic viability. Some clinicians advise spacing probiotic intake several hours apart from the antibiotic dose.
Rifaximin is not typically screened for in standard employment or athletic drug tests because it is a non-systemic antibiotic with low plasma concentrations.
The expiration date is printed on the packaging and is usually three to five years from the date of manufacture, provided the tablets are stored as directed.
No specific dietary restrictions are required. Patients may continue their usual diet, but they should avoid excessive alcohol, especially if being treated for hepatic encephalopathy.
Clinical studies show that many patients notice improvement in bowel frequency and stool consistency within 2-4 weeks of consistent twice-daily dosing.
Rifaximin is marketed under the brand name Xifaxan; generic versions may be available depending on local pharmacy supply, but they must contain the same active ingredient and meet regulatory standards.
